Ipilimumab-associated retinopathy

Jonathan Crews, Aniruddha Agarwal, Loren Jack, Ding Xu, Diana V. Do, Quan Dong Nguyen

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Ipilimumab is a novel immunotherapeutic agent that improves survival in patients diagnosed with metastatic melanoma. With the rising incidence of melanoma, the use of this pharmacologic agent is increasing. However, ipilimumab can be associated with rare but serious systemic adverse events. While the mechanism of these systemic adverse events is immune-related dysfunction, the index case highlights a possible direct ocular adverse event associated with ipilimumab infusion resulting in bilateral serous retinal detachment. Close observation of ocular findings using multimodal imaging analysis can provide insights into possible pathophysiology of the condition and guide further management.

Original languageEnglish (US)
Pages (from-to)658-660
Number of pages3
JournalOphthalmic Surgery Lasers and Imaging Retina
Volume46
Issue number6
DOIs
StatePublished - Jun 1 2015

Fingerprint

Melanoma
Multimodal Imaging
Retinal Detachment
Observation
Survival
Incidence
ipilimumab

ASJC Scopus subject areas

  • Surgery
  • Ophthalmology

Cite this

Crews, J., Agarwal, A., Jack, L., Xu, D., Do, D. V., & Nguyen, Q. D. (2015). Ipilimumab-associated retinopathy. Ophthalmic Surgery Lasers and Imaging Retina, 46(6), 658-660. https://doi.org/10.3928/23258160-20150610-10

Ipilimumab-associated retinopathy. / Crews, Jonathan; Agarwal, Aniruddha; Jack, Loren; Xu, Ding; Do, Diana V.; Nguyen, Quan Dong.

In: Ophthalmic Surgery Lasers and Imaging Retina, Vol. 46, No. 6, 01.06.2015, p. 658-660.

Research output: Contribution to journalArticle

Crews, J, Agarwal, A, Jack, L, Xu, D, Do, DV & Nguyen, QD 2015, 'Ipilimumab-associated retinopathy', Ophthalmic Surgery Lasers and Imaging Retina, vol. 46, no. 6, pp. 658-660. https://doi.org/10.3928/23258160-20150610-10
Crews J, Agarwal A, Jack L, Xu D, Do DV, Nguyen QD. Ipilimumab-associated retinopathy. Ophthalmic Surgery Lasers and Imaging Retina. 2015 Jun 1;46(6):658-660. https://doi.org/10.3928/23258160-20150610-10
Crews, Jonathan ; Agarwal, Aniruddha ; Jack, Loren ; Xu, Ding ; Do, Diana V. ; Nguyen, Quan Dong. / Ipilimumab-associated retinopathy. In: Ophthalmic Surgery Lasers and Imaging Retina. 2015 ; Vol. 46, No. 6. pp. 658-660.
@article{04134b2dd9024fdaac6aba05e82a17a1,
title = "Ipilimumab-associated retinopathy",
abstract = "Ipilimumab is a novel immunotherapeutic agent that improves survival in patients diagnosed with metastatic melanoma. With the rising incidence of melanoma, the use of this pharmacologic agent is increasing. However, ipilimumab can be associated with rare but serious systemic adverse events. While the mechanism of these systemic adverse events is immune-related dysfunction, the index case highlights a possible direct ocular adverse event associated with ipilimumab infusion resulting in bilateral serous retinal detachment. Close observation of ocular findings using multimodal imaging analysis can provide insights into possible pathophysiology of the condition and guide further management.",
author = "Jonathan Crews and Aniruddha Agarwal and Loren Jack and Ding Xu and Do, {Diana V.} and Nguyen, {Quan Dong}",
year = "2015",
month = "6",
day = "1",
doi = "10.3928/23258160-20150610-10",
language = "English (US)",
volume = "46",
pages = "658--660",
journal = "Ophthalmic Surgery Lasers and Imaging Retina",
issn = "2325-8160",
publisher = "Slack Incorporated",
number = "6",

}

TY - JOUR

T1 - Ipilimumab-associated retinopathy

AU - Crews, Jonathan

AU - Agarwal, Aniruddha

AU - Jack, Loren

AU - Xu, Ding

AU - Do, Diana V.

AU - Nguyen, Quan Dong

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Ipilimumab is a novel immunotherapeutic agent that improves survival in patients diagnosed with metastatic melanoma. With the rising incidence of melanoma, the use of this pharmacologic agent is increasing. However, ipilimumab can be associated with rare but serious systemic adverse events. While the mechanism of these systemic adverse events is immune-related dysfunction, the index case highlights a possible direct ocular adverse event associated with ipilimumab infusion resulting in bilateral serous retinal detachment. Close observation of ocular findings using multimodal imaging analysis can provide insights into possible pathophysiology of the condition and guide further management.

AB - Ipilimumab is a novel immunotherapeutic agent that improves survival in patients diagnosed with metastatic melanoma. With the rising incidence of melanoma, the use of this pharmacologic agent is increasing. However, ipilimumab can be associated with rare but serious systemic adverse events. While the mechanism of these systemic adverse events is immune-related dysfunction, the index case highlights a possible direct ocular adverse event associated with ipilimumab infusion resulting in bilateral serous retinal detachment. Close observation of ocular findings using multimodal imaging analysis can provide insights into possible pathophysiology of the condition and guide further management.

UR - http://www.scopus.com/inward/record.url?scp=84937036900&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937036900&partnerID=8YFLogxK

U2 - 10.3928/23258160-20150610-10

DO - 10.3928/23258160-20150610-10

M3 - Article

C2 - 26114847

AN - SCOPUS:84937036900

VL - 46

SP - 658

EP - 660

JO - Ophthalmic Surgery Lasers and Imaging Retina

JF - Ophthalmic Surgery Lasers and Imaging Retina

SN - 2325-8160

IS - 6

ER -